tim.hodson
Wed, 08/27/2025 – 11:13
Aug. 27, 2025 – Qureight recently announced that it has been selected by Calluna Pharma to support its Phase 2 AURORA study. Qureight will analyze imaging data from adult patients, evaluating anatomical lung changes in individuals treated with CAL101, Calluna’s lead asset for the treatment of idiopathic pulmonary fibrosis (IPF).
The ability to precisely and rapidly assess the efficacy of a promising novel therapy is particularly important for dis…